Search
Silicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or
Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & DSafflower oil
go.drugbank.com/drugs/DB09446ApprovedInvestigationalWithdrawnSafflower oil is approved for use as an indirect additive in food contact substances and is readily available as a food ingredient. … acid [A32677, A32679], depending on the flower type.
Strontium chloride
go.drugbank.com/drugs/DB13987ApprovedWithdrawnSuch strontium chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of the world [A33167, A33168]. … SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168].
Indium In-111 chloride
go.drugbank.com/drugs/DB09490ApprovedIt is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI. … and for radiolabeling Zevalin (ibritumomab tiuxetan) in preparations used for radioimmunotherapy procedures.
Synonyms: Indium chloride In-111, Indium In 111 chlorideMixtures: INDIO (111-IN) OSSINA CURIUM NETHERLANDS, Kit for the Preparation of Indium In 111 PentetreotideAcarbose
go.drugbank.com/drugs/DB00284ApprovedInvestigational[L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal … Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines.
Categories: Drugs Used in DiabetesCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019.
Categories: Compounds used in a research, industrial, or household settingEcallantide
go.drugbank.com/drugs/DB05311ApprovedBy reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … Hereditary angioedema is a rare autosomal dominant disorder with mutations to C1-esterase-inhibitor (C1-INH) located on Chromosome 11q, resulting in substantially lower levels of C4 and C1-INH activity
Categories: Drugs Used in Hereditary Angioedema, Analgesics, Non-NarcoticMethylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalMethylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. … FDA approved in 2008.
Catridecacog
go.drugbank.com/drugs/DB09310ApprovedCoagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … as the endogenously available form.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.